Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

OBJECTIVE The authors conducted a dose-finding study of D-cycloserine, a partial agonist at the glycine site of the N-methyl-D-aspartate subtype of the glutamate receptor, added to conventional neuroleptics for schizophrenic patients with prominent negative symptoms. METHOD Nine patients with schizophrenia completed consecutive 2-week trials of placebo and four doses of D-cycloserine. Clinical assessments were videotaped and were scored by a rater who was blind to temporal sequence. RESULTS D-Cycloserine at a dose of 50 mg/day produced a significant reduction (mean = 21%, SD = 28%) in negative symptoms and significantly improved reaction time as measured by Sternberg's Item Recognition Paradigm, a test mediated in part by prefrontal cortex. CONCLUSIONS This preliminary evidence suggests that D-cycloserine may improve negative symptoms and cognitive deficits over a narrow dose range when added to conventional antipsychotic agents.

[1]  T. O'donohue,et al.  Glycine modulation of the phencyclidine binding site in mammalian brain , 1988, Brain Research.

[2]  J. Fleiss,et al.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. , 1976, Archives of general psychiatry.

[3]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[4]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[5]  C. Cotman,et al.  Excitatory amino acid receptors in schizophrenia. , 1993, Schizophrenia bulletin.

[6]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[7]  P. Duffy,et al.  Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. , 1989, The Journal of pharmacology and experimental therapeutics.

[8]  T. Itil,et al.  d-Cycloserine therapy of psychosis by symptom provocation. , 1970, Comprehensive psychiatry.

[9]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[10]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[11]  P. Francis,et al.  d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain , 1991, Brain Research.

[12]  Brian A. Lawlor,et al.  Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? , 1992, Biological Psychiatry.